Por favor, use este identificador para citar o enlazar este ítem:http://uvadoc.uva.es/handle/10324/4201
Título
Ascorbate-dependent decrease of the mucosal immune inflammatory response to gliadin in coeliac disease patients
Autor
Año del Documento
2012
Editorial
Elsevier
Descripción
Producción Científica
Documento Fuente
Allergol. Immunopathol. (Madr.) 2012, vol. 40, n. 1. p.3-8
Abstract
Background: The IL-15/NF- B axis has an important role in coeliac disease (CD) and may represent
a molecular target for immunomodulation. Ascorbate (vitamin C) is known to show
inhibitory effects on NF- B. Therefore, we studied if ascorbate supplementation to gliadin
gliadin-stimulated biopsy culture could down-regulate the mucosal immune response to gliadin
in CD.
Methods: Duodenal biopsy explants from treated CD patients were gliadin challenged in vitro
(100 g/ml) with and without 20 mM ascorbate. An extra tissue explant in basal culture was
used as internal control. Secretion levels of nitrites (3 h), and IFN , TNF , IFN , IL-17, IL-13,
and IL-6 (24 h) were measured on the supernatants. IL-15 was assayed by western-blot on whole
protein duodenal explants.
Results: The addition of ascorbate to in vitro culture gliadin-challenged biopsies blocked the
secretion of nitrites (p = 0.013), IFN (p = 0.0207), TNF (p = 0.0099), IFN (p = 0.0375), and
IL-6 (p = 0.0036) compared to samples from non-ascorbate supplemented culture. Cytokine
secretion was downregulated by ascorbate even to lower values than those observed in basal
cultures (IFN : p = 0.0312; TNF : p = 0.0312; IFN : p = 0.0312; and IL-6: p = 0.0078). Gliadinchallenge
induced IL-15 production in biopsies from treated CD patients, while the addition
of ascorbate to culture medium completely inhibited IL-15 production. Moreover, the inhibition
of IL-15 by ascorbate took place even in the only treated CD-patient who had basal IL-15
production.
Conclusions: Ascorbate decreases the mucosal inflammatory response to gluten in an intestinal
biopsy culture model, so it might have a role in future supplementary therapy in CD.
© 2010 SEICAP. Published by Elsevier España, S.L. All rights reserve
Materias (normalizadas)
Enfermedad celíaca
ISSN
0301-0546
Revisión por pares
SI
Propietario de los Derechos
Elsevier-Doyma
Idioma
eng
Derechos
openAccess
Aparece en las colecciones
Files in questo item
La licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International